medwireNews: Patient-reported outcomes (PROs) and quality of life (QoL) are better with second-line osimertinib than chemotherapy in patients with T790M-positive advanced non-small-cell lung cancer (NSCLC), shows an analysis of the AURA 3 trial.
“The PRO data further substantiate the clinical meaningfulness of the statistically significant prolongation in [progression-free survival] with osimertinib over chemotherapy,” say the study authors.
“It supports regulatory approval and drug labeling and aids physicians and patients in treatment decision making.”
As assessed by the EORTC Core Quality of Life Questionnaire and the Lung Cancer Module, the time to deterioration for key symptoms including cough, chest pain, and dyspnea was significantly longer for the 279 participants who were randomly assigned to receive osimertinib than the 140 given pemetrexed alongside either carboplatin or cisplatin, with respective hazard ratios of 0.74, 0.52, and 0.42 in favor of the tyrosine kinase inhibitor.
And a significantly greater proportion of symptomatic patients in the osimertinib arm reported an improvement from baseline in global health status and QoL than their counterparts in the chemotherapy group, at 37% of 215 and 22% of 105, respectively.
These findings were reported by Chee Khoon Lee (St George Hospital, Kogarah, New South Wales, Australia) and colleagues in the Journal of Clinical Oncology.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group
See also: